Aug 18, 2026 · 6 min

Klarna cuts outlook as Amylyx rallies on trial results

Klarna Plunges, Amylyx Pharma Soars, Bath & Body Works Rallies

The episode shows how weaker consumer activity, clinical evidence, analyst upgrades, and earnings surprises are pulling premarket stocks in opposite directions.

3 key takeaways

1Klarna lowered its revenue outlook as weaker consumer activity pressured the fintech company’s premarket shares.
2Amylyx Pharmaceuticals surged after reporting positive late-stage trial results, making clinical news the session’s clearest catalyst.
3Fabrinet fell despite beating quarterly expectations, while Bath & Body Works rallied after a Citi upgrade.

Don't miss

Amylyx Pharmaceuticals surges on positive late-stage trial results, sharply contrasting with Klarna’s outlook-driven decline.

The brief

Klarna’s shares fell after the company lowered its revenue outlook and reported weaker consumer activity, turning a familiar fintech growth story into a warning about demand.

Amylyx Pharmaceuticals moved sharply higher on positive late-stage trial results, while Fabrinet declined despite beating quarterly expectations—evidence that the market rewards catalysts selectively.

Bath & Body Works rallied after a Citi upgrade, adding an analyst-driven move to a morning shaped by contrasting company-specific news.

The episode then shifts from markets to cities, previewing a discussion of AI-enabled urban systems, infrastructure, and Dubai’s long-term response to rapid population growth.

Taken together, the lineup shows why premarket moves require interpretation: forecasts, trial results, analyst views, and operating performance can point in different directions.

What was said on this episode

8 statements · 6 positive · 1 negative · 1 neutral

Katie Greifeldon KlarnaNegative0:53
Klarna’s second-quarter active consumers fell short of expectations.
“the number of active consumers, that's a big metric for them for the second quarter, missed expectations.”
Listen at 0:53
Katie Greifeldon Amylyx experimental drugPositive1:50
Amylyx’s experimental drug performed well in trials for post-bariatric-surgery hypoglycemia.
“they have a... an experimental drug that actually did very well in clinical trials for folks who experienced low blood sugar after bariatric surgery.”
Listen at 1:50
Katie Greifeldon Amylyx experimental drug FDA approvalPositive2:00
Amylyx plans to seek full FDA approval for its experimental drug.
“now they're going to take that to the FDA to try to get full approval.”
Listen at 2:00
Katie Greifeldon FabrinetPositive2:33
Fabrinet’s fourth-quarter results exceeded Wall Street targets.
“fourth quarter results, topping Wall Street targets.”
Listen at 2:33
Katie Greifeldon Bath & Body Works, Inc.Neutral3:15
Bath & Body Works will release earnings next Wednesday.
“this Bath & Body Works is going to be out with earnings next Wednesday.”
Listen at 3:15
Estefanía Tapiason AI in smart citiesPositive4:09
AI will accelerate and compress processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 4:09
Estefanía Tapiason Dubai urban responsePositive4:35
Dubai responded effectively to its sudden population increase.
“they reacted very well to it.”
Listen at 4:35
Estefanía Tapiason Dubai long-term urban planningPositive4:37
Dubai has a long-term urban planning vision uncommon worldwide.
“They have a long-term urban planning vision, which again doesn't happen everywhere in the world.”
Listen at 4:37

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.